Full-Time
Biomanufacturing Associate 2
Posted on 7/2/2026
GSK
10,001+ employees
Develops medicines, vaccines, and consumer health
No salary listed
King of Prussia, PA, USA
In Person
On-site role; remote work not available; shift work may include 12-hour days/nights.
Bachelor's, Associate's
 Biology & Biotech (1) |
|---|
Get referred to GSK
See people who can refer or advise you
- BS/BA degree, with cGMP manufacturing experience
- OR an Associate’s degree from Montgomery county community college in Biotechnology or related technical field with cGMP manufacturing experience
- OR High School degree, 1+ years of cGMP manufacturing experience.
- Demonstrate GSK Values – Patient Focus, Transparency, Respect, and Integrity – in every interaction, in every work task, and with every responsibility of the job role. Live GSK’s Expectations of Courage, Accountability, Development, and Teamwork to achieve high performing behaviors in the workplace.
- With good documentation and data integrity practices, safely and compliantly completes and documents daily manufacturing tasks per standard operating procedures, batch document instructions, and logbooks
- Proactively works with senior staff to achieve competency in production operations
- Supports in cross-functional activities, such as engineering actions, validation actions and Tech Transfer actions, including proactive safety and compliance input prior to execution. Primarily these activities are within the production suite, but sometimes require out of suite or off-site work (i.e. FAT support)
- Monitors equipment and critical process parameters, and escalates any issues or abnormalities and participating the resulting troubleshooting activities
- Strives to maintain a high level of competency with current and emerging digital platforms (SAP, EBR, AR/VR, etc)
- By learning the production schedule and assessing it daily, proactively ensures all processing equipment and necessary materials are adequate and available to set the team up for success
- Transparently participates in investigations that are the result of safety or compliance issues.
- Demonstrated level of high performance
- Strong verbal and written skills
- The ability to work well in a team environment
- Must be able to follow detailed processing instructions as well as accurately documenting all necessary documentation
GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.
Company Size
10,001+
Company Stage
IPO
Headquarters
London, United Kingdom
Founded
1891
Get referred to GSK
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 sales reached £8.4 billion, and specialty medicines grew 14%.
- GSK plans 25 late-stage studies by 2026, doubling earlier guidance.
- Arexvy and Blenrep won expanded 2026 approvals in Japan and China.
What critics are saying
- Dolutegravir loses exclusivity in 2028-2030, threatening Tivicay, Triumeq, and Dovato cash flows.
- Stevenage closes by 2029, and restructuring cuts jobs while execution risk rises.
- Zantac cases still linger in state courts; a bad oncology miss breaks the growth story.
What makes GSK unique
- Cambridge Biomedical Campus centers 1,000 scientists beside leading biotech, hospitals, and universities.
- GSK spans HIV, vaccines, respiratory, and oncology, reducing dependence on any single franchise.
- Relation Therapeutics and AI-led discovery sharpen GSK’s data-heavy, collaborative drug-discovery edge.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
401(k) Retirement Plan
Remote Work Options
Flexible Work Hours
Paid Vacation
Paid Holidays
Hybrid Work Options
Wellness Program
Mental Health Support
Phone/Internet Stipend
Company News
Maze Therapeutics announces appointments to its Board of Directors. Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze's Board of Directors, adding to the Company's deep bench of clinical and industry experience SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) - Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointments of Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., to its Board of Directors. "We are excited to welcome Paula and Sophie to our Board at this important time for our company. With key progress made in our development programs, we are looking ahead to several important milestones, including additional data from MZE829 in broad AMKD patients in late 2026 or early 2027, initial data from MZE782 in 2027, and additional trial initiations for both molecules next year," said Jason Coloma, Ph.D., chief executive officer of Maze. "As we continue to advance Maze's pipeline toward late-stage clinical development and pre-commercial planning, both Paula and Sophie will bring a wealth of clinical and business experience to support our mission to harness the power of genetics to transform the lives of patients." Dr. Johnson brings over 30 years of clinical and research experience, specializing in cardiology. She has served as President of Wellesley College since 2016 and currently serves on the Board of Directors of Johnson & Johnson (J&J). Previously, Dr. Johnson founded and served as the inaugural Executive Director of the Connors Center for Women's Health and Gender Biology at Brigham and Women's Hospital from 2002 to 2016, and served as the Chief of the Division of Women's Health at Brigham and Women's Hospital from 2002 to 2016. She previously served as a Clinical Epidemiologist at Brigham and Women's Hospital, as a Professor of Medicine at Harvard Medical School, and as Professor of Epidemiology at the Harvard School of Public Health. She holds an M.D. from Harvard Medical School, an M.P.H. from the Harvard T.H. Chan School of Public Health, and an A.B. from Harvard. Dr. Kornowski joins Maze's Board of Directors with more than 35 years of biopharmaceutical leadership experience, most recently serving as Chief Executive Officer of Boston Pharmaceuticals beginning in 2022, focusing the company's pipeline on candidates for liver disease and leading the company to its acquisition by GlaxoSmithKline (GSK). Previously, she served as a Senior Partner at Gurnet Point Capital. Dr. Kornowski was Executive Vice-President of Roche Partnering and a member of the Extended Corporate Executive Committee of F. Hoffmann-La Roche AG and a board member of Chugai Pharmaceuticals. In that role, she led partnering and M&A strategy across early-stage compounds, late-stage assets, and technology-driven biotech companies, working closely with R&D and Commercial teams at Roche and Genentech. Earlier in her career, she held several commercial leadership roles across geographies in leading innovative pharmaceutical and diagnostic companies in France, Israel, and the U.S., notably at Roche and Merck & Co. She holds a Pharm.D. from Paris Descartes University and an M.B.A. from the University of Chicago Booth School of Business. About Maze Therapeutics Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel small molecule precision medicines for patients with kidney and metabolic diseases. Guided by its Compass(TM) platform, Maze pursues genetically validated targets by integrating variant discovery and functionalization to discover and advance small molecule programs with first- or best-in-class potential. Maze's pipeline is led by MZE829, a dual-mechanism APOL1 inhibitor in Phase 2 development for APOL1-mediated kidney disease (AMKD), and MZE782, a SLC6A19 inhibitor in Phase 2 development with the potential to treat both phenylketonuria (PKU) and chronic kidney disease (CKD). Maze is headquartered in South San Francisco. For more information, please visit mazetx.com, or follow Maze on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current beliefs and expectations of management. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning the company's future plans and prospects, any expectations regarding the safety or efficacy of MZE829, MZE782 and other candidates under development, the ability of MZE829 to treat AMKD or other indications, the ability of MZE782 to treat PKU, CKD or other indications, the planned timing of the company's clinical trials, data results and further development of MZE829, MZE782 and other therapeutic candidates, and the company's ability to advance its pipeline towards late-stage clinical development. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "will," "predict" and similar expressions and their variants, as they relate to the company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the company believes the expectations reflected in such forward-looking statements are reasonable, the company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the company's forward-looking statements due to a variety of factors, including risks and uncertainties related to the company's ability to advance MZE829, MZE782 and its other therapeutic candidates, obtain regulatory approval of and ultimately commercialize the company's therapeutic candidates, the timing and results of preclinical studies and clinical trials, the company's ability to fund development activities and achieve development goals, its ability to protect its intellectual property, general business and economic conditions, and risks related to the impact on its business of macroeconomic conditions, including inflation, volatile interest rates, tariffs, instability in the global banking sector, and public health crises. Further information on potential risk factors that could affect the company's business and its financial results is detailed under the heading "Risk Factors" included in the documents the company files from time to time with the U.S. Securities and Exchange Commission, including the company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Africa SMB Journal do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
ILiAD appoints former GSK exec as Chief Business Officer. Antony Blanc is a seasoned biopharmaceutical executive with experience in corporate strategy, vaccine development and commercialization, business development and partnering. August 11, 2026 Associate Editor ILiAD Biotechnologies Inc., an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, has appointed Antony Blanc, former VP, Head of Global Marketing and Global Strategic Pricing at GSK Vaccines, as Chief Business Officer (CBO). Antony Blanc PhD is a seasoned biopharmaceutical executive with extensive experience in corporate strategy, vaccine development and commercialization, business development and partnering. Experience. Prior to ILiAD, Blanc served as Chief Business and Commercial Officer at CureVac as well as various global commercial leadership positions at GSK Vaccines and in McKinsey's European biotech practice. He brings a strong track record of building and executing growth strategies across clinical-stage and commercial organizations and will oversee ILiAD's business development, commercial and long-term value creation initiatives. "ILiAD has built a compelling platform with BPZE1 that has the potential to redefine pertussis vaccination and deliver meaningful public health benefit," said Blanc. "I'm excited to join the team at this pivotal moment and help guide the Company's strategic growth as it advances toward late-stage development and beyond."
UK laboratory space demand hit a record high, with rolling four-quarter take-up exceeding 1.2 million square feet in Q3 2026, according to CoStar data. The surge was driven by GSK's 300,000-square-foot prelet at Cambridge Biomedical Campus. Cambridge has led activity in 2026, with year-to-date leasing volumes above 180,000 square feet, nearly double Oxford's total. The first seven months of 2026 saw almost 500,000 square feet leased, matching the previous record year in 2015. However, UK laboratory vacancies reached a record 14.3% in Q2 2026, more than doubling in two years. The rise followed 1.8 million square feet of new lab space delivered across the Golden Triangle over the past two years. Construction activity has slowed significantly, with less than 130,000 square feet started on site in 2026, reducing the UK construction pipeline to around 3 million square feet.
GSK to invest £400m in new Cambridge R&D hub. August 4, 2026 Pharma giant GSK will invest £400 million in the creation of a new research hub in Cambridge, with the group planning to close the Stevenage site that it has maintained a presence at for more than 50 years as part of the move. [1] GSK is investing in the creation of a new global centre of excellence in R&D on the Cambridge Biomedical Campus. The 300,000 sq ft will feature state-of-the-art, tech-enabled laboratories and infrastructure and is set to form one of the main focal points for the company's drug discovery and development. According to GSK CEO Luke Miels, the move "will accelerate our R&D and help us deliver new, competitive products". Miels continued: "It integrates GSK further into one of the world's leading centres of knowledge and demonstrates the attractiveness of the UK's life sciences ecosystem.". The investment was described by Prime Minister Andy Burnham as "a vote of confidence in British business, a boost for home grown innovation and expertise, and a step towards more people getting access to new medicines and cutting edge treatments that will change lives for the better." The announcement comes in the wake of more than £3 billion of new public-private investment being made in the UK life sciences sector in the 12 months since the Department for Science, Innovation and Technology launched its plan for the industry. This plan lays out the government's ambition to establish the UK as the world's third largest life sciences sector economy by 2035, in addition to ensuring that patients treated by the NHS can benefit from new drugs and faster access to medicines. The UK's life sciences sector is a key driver of growth and jobs across the nation, employing approximately 360,000 people and generating around £147 billion in turnover. Get in touch. If you have any questions for our medical sales recruitment agency team please call us on 01424 777745 or drop us an email at [email protected] - we're very happy to help.
Nearly 800,000 sq ft of Golden Triangle lab space under offer after Q2 dip. Just under 800,000 sq ft of commercial space was under offer across the London-Oxford-Cambridge Golden Triangle at the end of July, promising a return to form for the market after a dip in leasing activity in Q2, according to Cushman & Wakefield. GSK is agreed to take a 300,000 sq ft new R&D centre at Discovery Drive, Cambridge Biomedical Campus Life science take-up across the Golden Triangle stood at 175,000 sq ft in Q2, 8% below the five-year quarterly average and 57% below the surge in Q1. However, at the close of Q2, 779,200 sq ft was under offer, including GSK's proposed deal for a 300,000 sq ft new R&D centre at Discovery Drive on the Cambridge Biomedical Campus. Cushman & Wakefield said that should these deals be completed as expected, leasing in H2 2026 could return to the stronger levels recorded across the previous two quarters. In Q2, London lead leasing activity, accounting for 56% of the quarterly volume with five deals totalling 98,300 sq ft. The majority of this came from an unnamed occupier taking the 85,000 sq ft Jahn Court in the Regent Quarter Campus. Cambridge recorded 48,500 sq ft across three deals, while two deals in oxford added 28,200 sq ft. Prime quoting rents held steady across the three cities for the fifth consecutive quarter, at £140/sq ft in London, £77/sq ft in Cambridge and £70/sq ft in Oxford. C&W rates all three markets as 'under pressure' as space remains constrained, with elevated construction and financing costs, geopolitical uncertainty and higher vacancy rates constraining speculative development. Despite this, at the close of Q2, 2.9m sq ft of laboratory space was under construction across the Golden Triangle, with around 2.2m sq ft of speculative space scheduled for completion over the next three years. Development continues to moderate, the report said, with the volume under construction at its lowest level since Q1 2024. Planning consent has been secured for a further 4.2m sq ft, which should be developed by 2029. The report says UK life science companies raised just over £2bn in venture capital in Q2, the strongest quarter for VC investment in over a year, up 135% on Q1 and 102% above the five-year quarterly average. Golden Triangle life sciences investment volumes totalled £160m from two transactions, the largest being British Land's acquisition of the Life Sciences REIT portfolio for £150m, while Wrenbridge and Investec Realis acquired a three-acre site in North Cambridge from the Coulson Building Group for £10m, with plans to develop it into a commercial and life sciences hub. C&W said investment during H1 reflected a challenging environment and while there are early signs of improving sentiment, it warned that expectations of a marked recovery "should remain measured".